Disease Info Card

Li-fraumeni Syndrome

Information about Li-fraumeni Syndrome: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Li-fraumeni Syndrome

Most recent studies have shown that Li-fraumeni Syndrome shares some biological mechanisms with ataxia-telangiectasia, brain-neoplasms, carcinoma, cell-transformation-neoplastic, germline-mutation-abnormality, hereditary-malignant-neoplasm, leukemia, malignant-neoplasm-of-adrenal-cortex, malignant-neoplasm-of-breast, malignant-neoplasms, malignant-paraganglionic-neoplasm, mammary-neoplasms, neoplasms, neoplastic-syndromes-hereditary, neurofibromatoses, osteosarcoma, retinoblastoma, rhabdomyosarcoma, sarcoma, tumors-of-adrenal-cortex.

Among the many pathways, these few ones have gauged particular interests from scientists studying Li-fraumeni Syndrome, and have been seen in publications frequently: Aging, Cell Cycle, Cell Cycle Arrest, Cell Cycle Checkpoint, Cell Death, Cell Growth, Cell Killing, Cell Proliferation, Cellular Senescence, Dna Methylation, Dna Repair, Dna Replication, Induction Of Apoptosis, Localization, Methylation, Mismatch Repair, Oncogenesis, Pathogenesis, Replicative Senescence, Senescence

Quite a number of genes have been found to play important roles in Li-fraumeni Syndrome, such as APC, ATM, BRCA1, BRCA2, CDH1, CDK4, CDKN1A, CDKN2A, CHEK2, MDM2, MLH1, MSH2, NSG1, PAK3, PROC, PTEN, RB1, TCEAL1, TP53. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.